Cybin (CYBN) Competitors $9.09 -0.24 (-2.57%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$9.04 -0.04 (-0.50%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CYBN vs. NUVB, PRTA, CRON, GHRS, BCAX, VERV, MNMD, DNTH, AVXL, and OPTShould you be buying Cybin stock or one of its competitors? The main competitors of Cybin include Nuvation Bio (NUVB), Prothena (PRTA), Cronos Group (CRON), GH Research (GHRS), Bicara Therapeutics (BCAX), Verve Therapeutics (VERV), Mind Medicine (MindMed) (MNMD), Dianthus Therapeutics (DNTH), Anavex Life Sciences (AVXL), and Opthea (OPT). These companies are all part of the "pharmaceutical products" industry. Cybin vs. Nuvation Bio Prothena Cronos Group GH Research Bicara Therapeutics Verve Therapeutics Mind Medicine (MindMed) Dianthus Therapeutics Anavex Life Sciences Opthea Cybin (NYSE:CYBN) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends. Does the media refer more to CYBN or NUVB? In the previous week, Nuvation Bio had 1 more articles in the media than Cybin. MarketBeat recorded 2 mentions for Nuvation Bio and 1 mentions for Cybin. Nuvation Bio's average media sentiment score of 0.97 beat Cybin's score of 0.50 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in CYBN or NUVB? 17.9% of Cybin shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 5.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher earnings and valuation, CYBN or NUVB? Cybin is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$4.38-2.07Nuvation BioN/AN/A-$75.80M-$2.17-1.02 Which has more risk and volatility, CYBN or NUVB? Cybin has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Does the MarketBeat Community believe in CYBN or NUVB? Nuvation Bio received 33 more outperform votes than Cybin when rated by MarketBeat users. However, 100.00% of users gave Cybin an outperform vote while only 80.00% of users gave Nuvation Bio an outperform vote. CompanyUnderperformOutperformCybinOutperform Votes15100.00% Underperform VotesNo VotesNuvation BioOutperform Votes4880.00% Underperform Votes1220.00% Do analysts recommend CYBN or NUVB? Cybin currently has a consensus target price of $111.50, suggesting a potential upside of 1,126.62%. Nuvation Bio has a consensus target price of $8.20, suggesting a potential upside of 271.88%. Given Cybin's higher possible upside, equities analysts plainly believe Cybin is more favorable than Nuvation Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CYBN or NUVB more profitable? Nuvation Bio's return on equity of -21.89% beat Cybin's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Nuvation Bio N/A -21.89%-17.86% SummaryNuvation Bio beats Cybin on 10 of the 14 factors compared between the two stocks. Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYBN vs. The Competition Export to ExcelMetricCybinPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$197.17M$7.07B$5.84B$20.31BDividend YieldN/A2.75%4.75%3.64%P/E Ratio-2.075.4725.4734.71Price / SalesN/A306.08447.5815.49Price / CashN/A65.6738.0120.26Price / Book0.846.717.644.80Net Income-$57.88M$138.33M$3.18B$1.02B7 Day Performance-4.62%-2.61%-1.99%-1.07%1 Month Performance-9.19%-2.32%-0.42%-1.11%1 Year PerformanceN/A-5.31%16.51%13.69% Cybin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYBNCybin2.3389 of 5 stars$9.09-2.6%$111.50+1,126.6%N/A$197.17MN/A-2.0750NUVBNuvation Bio2.0445 of 5 stars$2.28-0.7%$8.20+260.4%+23.9%$765.70MN/A-1.0560PRTAProthena3.125 of 5 stars$14.17+2.0%$46.50+228.2%-42.5%$762.49M$91.37M-5.71130Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpCRONCronos Group1.2635 of 5 stars$1.97-1.5%$3.00+52.3%-10.0%$753.58M$87.24M-15.15450GHRSGH Research2.5113 of 5 stars$14.31flat$30.25+111.4%+62.2%$744.52MN/A-18.1110Gap UpBCAXBicara TherapeuticsN/A$13.48+2.7%$41.20+205.6%N/A$733.58MN/A0.0032VERVVerve Therapeutics2.921 of 5 stars$8.58+11.3%$25.75+200.1%-44.6%$726.42M$24.40M-3.49110Upcoming EarningsAnalyst ForecastMNMDMind Medicine (MindMed)2.1419 of 5 stars$9.89+14.3%$26.33+166.3%+65.2%$725.25MN/A-4.3840Gap UpHigh Trading VolumeDNTHDianthus Therapeutics1.7679 of 5 stars$24.49+1.5%$46.83+91.2%-1.3%$724.90M$2.83M-9.8080AVXLAnavex Life Sciences3.7896 of 5 stars$8.52+0.6%$44.00+416.4%+64.4%$722.67MN/A-16.3840Analyst ForecastAnalyst RevisionGap UpOPTOpthea2.0626 of 5 stars$5.21+1.0%$12.00+130.3%+46.8%$710.80M$120,000.000.008Upcoming Earnings Related Companies and Tools Related Companies NUVB Competitors PRTA Competitors CRON Competitors GHRS Competitors BCAX Competitors VERV Competitors MNMD Competitors DNTH Competitors AVXL Competitors OPT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CYBN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
